Scinai Immunotherapeutics

SCNI - Scinai ImmunotherapeuticsFinancials

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2016
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2017
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
0
10
-
0%
25
-5
L
14
1.4
-11
-1
1
-11
0
0
-
-
12/2024
1
9
-
3,400%
28
10
220%
-2
-
-7
-0
3
-7
0
0
-
-
12/2025
1
4
-
170%
0.96
8
28%
-1
-
-6
-0
6
-6
0
0
-
-